Relationship between Long Noncoding RNA H19 Polymorphisms and Risk of Coronary Artery Disease in a Chinese Population: A Case-Control Study

Wei-na Hu,1 Han-xi Ding,2 Qian Xu,2 Xue-ying Zhang,1 Da-tong Yang,3 and Yuan-zhe Jin1

1Department of Cardiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110034, China
2Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Affiliated Hospital of China Medical University, Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education Department, Shenyang, Liaoning 110001, China
3China Medical University, China

Correspondence should be addressed to Yuan-zhe Jin; yzjin@cmu.edu.cn

Background/Aim. Coronary artery disease (CAD) is a major health problem that has high morbidity and mortality around the world. In recent years, long noncoding RNA H19 has been reported to affect the proliferation and apoptosis of vascular cells, which directly or indirectly results in atherosclerosis. We performed a case-control study to explore the relationship between H19 gene polymorphisms (rs2735971, rs2839698, and rs3024270) and the risk of CAD.

Methods. We collected 732 samples from Liaoning Province, China, and three polymorphisms in long noncoding RNA H19 were genotyped using the KASP platform.

Results. Our data showed that H19 rs2735971 and rs3024270 variant genotypes were associated with a decreased risk of CAD (rs2735971, \( P = 0.003 \), odds ratio (OR) = 0.6195, 95% confidence interval = 0.44 – 0.84; rs3024270, \( P = 0.030 \), OR = 0.65, 95% confidence interval = 0.44 – 0.96). No significant association with the risk of CAD was found for H19 rs2839698 polymorphism (\( P > 0.05 \)). In haplotype analysis, H19 polymorphisms of rs2735971-rs2839698-rs3024270 A-C-C haplotype reduced the risk of CAD by 0.61-fold (\( P = 0.004 \), OR = 0.61, 95% confidence interval = 0.43 – 0.86). In addition, we found that rs2839698 interacted with smoking (\( P_{\text{interaction}} = 0.027 \)), and according to multifactor dimensionality reduction analysis, the three-factor model including H19 rs2839698-smoking-drinking was the best model for the risk of CAD (testing balanced accuracy = 0.6979).

Conclusion. Our study demonstrated that some genotypes of H19 rs2735971 and rs3024270 polymorphisms, as well as rs2735971-rs2839698-rs3024270 A-C-C haplotype, were associated with the risk of CAD in a Chinese population, and these genotypes have the potential to be biomarkers for predicting CAD risk. We also found that rs2735971-rs2839698-rs3024270 A-C-C may have a significantly lower risk of CAD. The recessive genetic model of rs3024270 could predict the severity of CAD.

1. Introduction

Coronary artery disease (CAD) is a major health problem, with high morbidity and mortality around the world [1]. Reports of cardiovascular diseases in China in 2017 [2] show that CAD is still on the rise. In addition, 11 million Chinese people have CAD, and 3.4 million will die of the disease in the next 20 years.

CAD is a multifactorial disease with modifiable and non-modifiable risk factors. Genetic factors account for about 50% of the susceptibility to CAD according to a genome-wide association study (GWAS), which established the important role of genetic influences in CAD [3–5].

Long noncoding RNAs (lncRNAs) are important members of the noncoding RNA family and have become a hot topic in the field of life science research in recent
years [6–9]. Studies over the past few years have found that multiple lncRNAs, namely, MIAT, ANRIL, lincRNA-p21, AC100865.1, OTTHUMT0000387022, NONHSAT112178, Novlnc6, MALAT1, LIPCAR, and SRA, have important functions in CAD [10]. However, the role of lncRNAs remains unclear.

As an important member of the lncRNA family, lncRNA H19 has been reported to affect the proliferation and apoptosis of vascular cells, which directly or indirectly results in atherosclerosis [11]. The H19 gene is located in the human chromosome 11p15.5 region and is approximately 2300 bp long [12]. H19 is a typical paternally imprinted and maternally expressed gene. It is induced in the embryonic stage and decreases after birth but remains in skeletal muscle and the heart in adults. Recent research has shown that H19 is expressed in human atherosclerotic plaques and vascular calcification in a rat model [10–13], indicating that it may be involved in the development of CAD. Thus, we supposed that H19 may be involved in the development of CAD and H19 single nucleotide polymorphisms (SNPs) may be associated with the risk of CAD.

We therefore performed a case-control study of the candidate polymorphisms of the H19 gene and CAD in a Chinese population. The aim of this study was to identify predictive biomarkers for CAD risk and establish an experimental basis to improve our understanding of the etiology and mechanisms of CAD.

2. Materials and Methods

2.1. Patients. The Ethical Committee of the Fourth Affiliated Hospital of the China Medical University approved this research project, and written informed consent was obtained from all participants. All clinical investigations were conducted according to the principles described in the Declaration of Helsinki. We recruited 732 participants for this study, including 366 CAD patients and 366 matched controls. CAD diagnosis was based on electrocardiogram, echocardiography, blood tests, coronary angiography, and cardiac catheterization. The severity of CAD was assessed by coronary artery and Gensini score [14, 15]. Sex- and age-matched controls (n = 366) were recruited from a community health screening program in the same area, Liaoning Province, China, from 2012 to 2014. Peripheral venous blood specimens were collected from participants and stored at −20°C until use.

2.2. SNP Selection and Genotyping. Genetic polymorphisms were screened using the HapMap database. Haplovlew 4.2 was used to select among the Chinese Beijing Han population an unbalanced R2 value of greater than 0.8 and a minimum allele frequency greater than 5%. F-SNP software (http://compbio.cs.queensu.ca/F-SNP/) was used to predict the possible functions of these selected sites. Lastly, we selected H19 tag SNPs according to the literature [8, 16]. The most common SNPs on the H19 gene were rs2735971, rs2839698, rs3024270, and rs217727.

Genomic DNA was extracted using a previously published method and diluted to a working concentration of 20 ng L⁻¹ for genotyping. Gene Company Ltd. (Shanghai, China) performed the assay using allele-specific PCR with KASP reagents (LGC Genomics, Hoddesdon, UK). For quality control, we repeatedly genotyped 10% of the total samples at once. The concordance rate of these repeated samples reached 100%, which demonstrated that the genotyping results were reliable. Five percent of each sample was used for sequencing.

2.3. Statistical Analysis. Between-group differences of sex as well as the Hardy–Weinberg equilibrium were compared using the χ² test, and analysis of variance was performed for age variability. Multivariate logistic regression with adjustments for age and sex was used to show the association between selected gene polymorphisms and CAD risk. The haplotype of each gene was analyzed using SHEsis software [17]. All H19 gene polymorphisms identified in the best models of gene–gene interactions were calculated using MDR software (version 3.0.2). The combined effect of selected SNP–SNP interactions in the best model was determined by multivariate logistic regression adjusted for age and sex. The associations between gene polymorphisms and clinical parameters were examined using the χ² test; the differences in the clinical parameters among the different polymorphism groups were compared using the t-test. A P value of less than 0.05 was considered statistically significant.

3. Results

3.1. Baseline Characteristics of the Subjects. The demographic characteristics of CAD and control subjects are shown in Supplementary Table S1. There were no significant differences in age (57.4 ± 8.8 vs. 57.1 ± 7.6) or sex (male 75.7% vs. 76.0%) between the CAD and control groups.

3.2. Association between SNPs with lncRNA H19 Gene and CAD Risk. We genotyped all four polymorphisms of lncRNA H19 gene, but rs217727 polymorphism was the same wild-type CC in both CAD and control groups. This polymorphism was therefore not considered for subsequent analysis.

We investigated the association between H19 polymorphisms and the risk of CAD (Table 1). The three polymorphisms all conformed to the Hardy–Weinberg equilibrium. We also analyzed the effectiveness of the test. For rs2735971, 1 − β = 0.903 and α = 0.041, which suggested significant associations. We found that individuals with H19 rs2735971 variant GA genotype had a 0.59-fold lower risk of CAD (P = 0.003, OR = 0.59, 95% confidence interval (CI) = 0.42–0.83). The recessive and allele models also showed reduced risk of CAD by 0.61- and 0.68-fold, respectively (P = 0.003, OR = 0.61, 95% CI = 0.44–0.84; P = 0.008, OR = 0.68, 95% CI = 0.51–0.91, respectively). The H19 rs3024270 polymorphism was associated with a 0.65-fold lower risk of CAD in a recessive model (P = 0.030, OR = 0.65, 95% CI = 0.44–0.96). However, we found no significant association between H19 rs2839698 polymorphisms and risk of CAD (P > 0.05).

3.3. Association between lncRNA H19 Polymorphisms and CAD Risk Stratified by Individual Characteristics. To explore
the effects of other factors on the association, we further performed stratified analysis according to different CAD factors (Table 2). We considered that the absolute value of the stratified odds ratio (OR) closer to zero than the overall OR was more significant. In the dominant model, rs2735971 polymorphism showed a more significant association with a lower risk of CAD in the women ($P = 0.012$, $OR = 0.40$, $95\% CI = 0.19 - 0.82$), nonsmoker ($P = 0.028$, $OR = 0.54$, $95\% CI = 0.31 - 0.94$), nondrinker ($P = 0.028$, $OR = 0.59$, $95\% CI = 0.37 - 0.94$), and younger age ($P = 0.017$, $OR = 0.60$, $95\% CI = 0.39 - 0.91$) subgroups. The allele model of rs4102217 showed lower risk of CAD in the women ($P = 0.007$, $OR = 0.43$, $95\% CI = 0.23 - 0.79$) and non-drinker ($P = 0.027$, $OR = 0.63$, $95\% CI = 0.42 - 0.95$) subgroups. In addition, we found that in the dominant model, the H19 rs2839698 polymorphism was associated with an increased risk of CAD in the women ($P = 0.002$, $OR = 2.62$, $95\% CI = 1.40 - 4.88$), elderly ($P = 0.015$, $OR = 1.80$, $95\% CI = 1.12 - 2.89$), and nonsmoker ($P = 0.023$, $OR = 1.76$, $95\% CI = 1.08 - 2.87$) subgroups. The allele model of rs2839698 showed an increased risk of CAD in women ($P = 0.004$, $OR = 2.12$, $95\% CI = 1.28 - 3.50$) and in never smokers ($P = 0.024$, $OR = 1.56$, $95\% CI = 1.06 - 2.29$). Moreover, in the recessive model, the H19 rs3024270 polymorphism demonstrated lower risk of CAD in the men ($P = 0.006$, $OR = 0.53$, $95\% CI = 0.34 - 0.83$), younger age ($P = 0.033$, $OR = 0.53$, $95\% CI = 0.36 - 0.96$), and ever smokers ($P = 0.009$, $OR = 0.51$, $95\% CI = 0.31 - 0.85$) subgroups. The allele model of rs3024270 showed lower risk of CAD in men ($P = 0.035$, $OR = 0.77$, $95\% CI = 0.61 - 0.98$) and smokers ($P = 0.050$, $OR = 0.76$, $95\% CI = 0.58 - 1.00$).

### 3.4. Association between Haplotype of H19 SNPs and CAD Risk.
Haplotypes with a frequency of less than 0.03 were excluded from analysis (Table 3). Haplotype analysis suggested that rs2735971-rs2839698-rs3024270 A-C-C had a significantly lower risk of CAD ($P = 0.004$, $OR = 0.61$, $95\% CI = 0.43 - 0.86$) than did the other haplotypes combined.

### 3.5. Epistatic Effects of Pairwise Interacting Factors on the Risks of CAD.
We analyzed the epistatic effects between the pairs of the interacting SNPs and risk of CAD (Table 4). For H19 rs2735971, the AA+AG genotype was found to be associated with a lower risk of CAD ($P = 0.017$, $OR = 0.59$, $95\% CI = 0.38 - 0.91$), but only in the presence of CC genotype at H19 rs2839698. For H19 rs2735971, the dominant model was found to be associated with a decreased risk of CAD ($P = 0.021$, $OR = 0.64$, $95\% CI = 0.44 - 0.93$), but only

---

### Table 1: Association of IncRNA H19 polymorphisms and risk of CAD.

| SNPs        | NCBI Ref. | CON (%) | CAD (%) | $p$  | CAD vs. CON |
|-------------|-----------|---------|---------|------|-------------|
| H19 rs2735971 |           |         |         |      |             |
| GG          | 26 (63.4) | 211 (62.24) | 239 (73.09) | 1 (Ref) |             |
| GA          | 14 (34.1) | 118 (34.81) | 79 (24.16)  | 0.003 | 0.59 (0.42-0.83) |
| AA          | 1 (2.4)   | 10 (2.95)  | 9 (2.75)  | 0.596 | 0.78 (0.31-1.96) |
| AA+GA vs. GG|           |         |         | 0.003 | 0.61 (0.44-0.84) |
| AA vs. GA+GG |           |         |         | 0.867 | 0.93 (0.37-2.31) |
| A vs. G     |           |         |         | 0.008 | 0.68 (0.51-0.91) |
| $P_{\text{HWE}}$ | 0.577 | 0.175 | | | |
| H19 rs2839698 |           |         |         |      |             |
| CC          | 26 (57.8) | 200 (55.10) | 181 (50.99) | 1 (Ref) |             |
| CT          | 17 (38.3) | 130 (35.81) | 148 (41.69) | 0.146 | 1.26 (0.92-1.72) |
| TT          | 3 (6.7)   | 33 (9.09)  | 26 (7.32) | 0.583 | 0.86 (0.49-1.49) |
| CT+TT vs. CC|           |         |         | 0.258 | 1.19 (0.88-1.59) |
| TT vs. CT+CC|           |         |         | 0.397 | 0.79 (0.46-1.36) |
| T vs. C     |           |         |         | 0.601 | 1.06 (0.84-1.34) |
| $P_{\text{HWE}}$ | 0.922 | 0.081 | | | |
| H19 rs3024270 |           |         |         |      |             |
| GG          | 5 (21.7) | 120 (33.43) | 120 (34.09) | 1 (Ref) |             |
| GC          | 9 (39.2) | 162 (45.13) | 179 (50.85) | 0.586 | 1.10 (0.79-1.53) |
| CC          | 9 (39.2) | 77 (21.44)  | 53 (15.06) | 0.102 | 0.70 (0.45-1.07) |
| CC+GC vs. GG|           |         |         | 0.856 | 0.97 (0.71-1.33) |
| CC vs. GC+GG|           |         |         | 0.030 | 0.65 (0.44-0.96) |
| C vs. G     |           |         |         | 0.185 | 0.87 (0.70-1.07) |
| $P_{\text{HWE}}$ | 0.355 | 0.110 | | | |

---

*Logistic regression adjusted by sex and age. *Hardy–Weinberg equilibrium in the population. CAD: coronary artery disease; CI: confidence interval; CON: control; NCBI Ref.: number of references to studies of these polymorphisms in the Chinese Beijing Han population in the NCBI database; OR: odds ratio.
| Variables               | Genotype | ACS vs. CON | \( P^a \) | OR (95% CI)   |
|-------------------------|----------|-------------|-----------|--------------|
| **H19 rs2735971**       |          |             |           |              |
| Gender                  |          |             |           |              |
| Male                    |          |             |           |              |
|                         | GG       | 176/162     | 1 (Ref.)  |              |
|                         | GA       | 65/93       | 0.024     | 0.64 (0.44-0.94) |
|                         | AA       | 7/4         | 0.452     | 1.61 (0.46-5.62) |
|                         | GA+AA vs. GG | 0.045     | 0.68 (0.47-0.99) |
|                         | AA vs. GA+GG | 0.330     | 1.85 (0.54-6.41) |
|                         | A vs. G  | 0.137       | 0.78 (0.66-1.08) |
|                         | GG       | 63/49       | 1 (Ref.)  |              |
|                         | GA       | 14/25       | 0.028     | 0.43 (0.20-0.91) |
|                         | AA       | 2/6         | 0.101     | 0.25 (0.05-1.31) |
|                         | GA+AA vs. GG | 0.045     | 0.68 (0.47-0.99) |
|                         | AA vs. GA+GG | 0.174     | 0.32 (0.06-1.65) |
|                         | A vs. G  | 0.007       | 0.43 (0.23-0.79) |
| Female                  |          |             |           |              |
|                         | GG       | 63/49       | 1 (Ref.)  |              |
|                         | GA       | 14/25       | 0.028     | 0.43 (0.20-0.91) |
|                         | AA       | 2/6         | 0.101     | 0.25 (0.05-1.31) |
|                         | GA+AA vs. GG | 0.045     | 0.68 (0.47-0.99) |
|                         | AA vs. GA+GG | 0.174     | 0.32 (0.06-1.65) |
|                         | A vs. G  | 0.007       | 0.43 (0.23-0.79) |
| Age                     |          |             |           |              |
|                         | GG       | 143/121     | 1 (Ref.)  |              |
|                         | GA       | 51/76       | 0.010     | 0.57 (0.37-0.88) |
|                         | AA       | 5/3         | 0.783     | 1.23 (0.28-5.34) |
| ≤60                     |          |             |           |              |
|                         | GA+AA vs. GG | 0.017     | 0.60 (0.39-0.91) |
|                         | AA vs. GA+GG | 0.529     | 1.59 (0.37-6.80) |
|                         | A vs. G  | 0.064       | 0.65 (0.41-1.03) |
|                         | GG       | 96/90       | 1 (Ref.)  |              |
|                         | GA       | 28/42       | 0.134     | 0.65 (0.37-1.14) |
|                         | AA       | 4/7         | 0.444     | 0.60 (0.17-2.20) |
| >60                     |          |             |           |              |
|                         | GA+AA vs. GG | 0.102     | 0.64 (0.37-1.09) |
|                         | AA vs. GA+GG | 0.525     | 0.66 (0.19-2.37) |
|                         | A vs. G  | 0.056       | 0.70 (0.49-1.01) |
| Smoking                 |          |             |           |              |
|                         | GG       | 161/112     | 1 (Ref.)  |              |
|                         | GA       | 58/63       | 0.041     | 0.63 (0.41-0.98) |
|                         | AA       | 5/4         | 0.903     | 0.92 (0.24-3.52) |
| Ever smoker             |          |             |           |              |
|                         | GA+AA vs. GG | 0.047     | 0.65 (0.43-0.99) |
|                         | AA vs. GA+GG | 0.926     | 1.07 (0.28-4.03) |
|                         | A vs. G  | 0.087       | 0.72 (0.50-1.05) |
|                         | GG       | 78/99       | 1 (Ref.)  |              |
|                         | GA       | 21/55       | 0.026     | 0.51 (0.28-0.92) |
|                         | AA       | 4/6         | 0.675     | 0.76 (0.20-2.81) |
| Never smoker            |          |             |           |              |
|                         | GA+AA vs. GG | 0.028     | 0.54 (0.31-0.94) |
|                         | AA vs. GA+GG | 0.901     | 0.92 (0.25-3.39) |
|                         | A vs. G  | 0.055       | 0.63 (0.39-1.01) |
| Alcohol drinking        |          |             |           |              |
|                         | GG       | 56/119      | 1 (Ref.)  |              |
|                         | GA       | 27/76       | 0.345     | 0.77 (0.45-1.33) |
|                         | AA       | 4/4         | 0.314     | 2.08 (0.50-8.63) |
| Drinker                 |          |             |           |              |
|                         | GA+AA vs. GG | 0.491     | 0.83 (0.49-1.41) |
|                         | AA vs. GA+GG | 0.256     | 2.27 (0.55-9.28) |
|                         | A vs. G  | 0.806       | 0.95 (0.62-1.48) |
| Nondrinker              |          |             |           |              |
|                         | GG       | 183/92      | 1 (Ref.)  |              |
| Variables   | Genotype   | ACS vs. CON | \(P^a\) | OR (95% CI) |
|------------|------------|-------------|---------|-------------|
| GA         | 52/42      | 0.041       | 0.60 (0.37-0.98) |
| AA         | 5/6        | 0.298       | 0.52 (0.15-1.79) |
| GA+AA vs. GG | 0.028    |             | 0.59 (0.37-0.94) |
| AA vs. GA+GG | 0.417    |             | 0.60 (0.18-2.05) |
| A vs. G      | 0.027      |             | 0.63 (0.42-0.95) |

| H19 rs2839698   |         |             |         |             |
|-----------------|---------|-------------|---------|-------------|
| Gender          |         |             |         |             |
|                 | CC      | 140/139     | 1 (Ref.)|             |
|                 | CT      | 111/109     | 0.934   | 1.02 (0.71-1.45) |
|                 | TT      | 17/28       | 0.109   | 0.59 (0.31-1.13) |
| Male            |         |             |         |             |
|                 | CT+TT vs. CC | 0.669    | 0.93 (0.66-1.30) |
|                 | TT vs. CT+CC | 0.112    | 0.60 (0.32-1.13) |
|                 | T vs. C  | 0.305       | 0.87 (0.67-1.13) |
|                 | CC      | 41/61       | 1 (Ref.)|             |
|                 | CT      | 37/21       | 0.005   | 2.61 (1.34-5.09) |
|                 | TT      | 9/5         | 0.097   | 2.68 (0.84-8.58) |
| Female          |         |             |         |             |
|                 | CT+TT vs. CC | 0.002    | 2.62 (1.40-4.88) |
|                 | TT vs. CT+CC | 0.284    | 1.86 (0.60-5.81) |
|                 | T vs. C  | 0.004       | 2.12 (1.28-3.50) |
| Age             |         |             |         |             |
| \(\leq 60\)    | CC      | 113/111     | 1 (Ref.)|             |
|                 | CT      | 80/84       | 0.710   | 0.93 (0.62-1.39) |
|                 | TT      | 17/20       | 0.589   | 0.82 (0.41-1.66) |
| \(\leq 60\)    | CT+TT vs. CC | 0.640    | 0.91 (0.62-1.34) |
|                 | TT vs. CT+CC | 0.671    | 0.86 (0.44-1.70) |
|                 | T vs. C  | 0.147       | 1.31 (0.91-1.89) |
|                 | CC      | 68/89       | 1 (Ref.)|             |
|                 | CT      | 68/46       | 0.006   | 2.02 (1.22-3.34) |
|                 | TT      | 9/13        | 0.997   | 1.00 (0.40-2.51) |
| \(>60\)        | CT+TT vs. CC | 0.015    | 1.80 (1.12-2.89) |
|                 | TT vs. CT+CC | 0.511    | 0.74 (0.30-1.81) |
|                 | T vs. C  | 0.603       | 0.92 (0.68-1.25) |
| Smoking         |         |             |         |             |
| Ever smoker     | CC      | 126/93      | 1 (Ref.)|             |
|                 | CT      | 103/79      | 0.968   | 0.99 (0.66-1.48) |
|                 | TT      | 14/20       | 0.062   | 0.49 (0.23-1.04) |
| Never smoker    | CT+TT vs. CC | 0.552    | 0.89 (0.61-1.31) |
|                 | TT vs. CT+CC | 0.073    | 0.52 (0.25-1.06) |
|                 | T vs. C  | 0.221       | 0.83 (0.62-1.12) |
|                 | CC      | 55/107      | 1 (Ref.)|             |
|                 | CT      | 45/51       | 0.041   | 1.72 (1.02-2.90) |
|                 | TT      | 12/13       | 0.172   | 1.81 (0.77-4.24) |
| Alcohol drinking|         |             |         |             |
| Drinker         | CC      | 51/111      | 1 (Ref.)|             |
|                 | CT      | 35/80       | 0.794   | 0.93 (0.55-1.57) |
| Variables | Genotype | ACS vs. CON | OR (95% CI) |
|-----------|----------|-------------|-------------|
|           |          | P<sup>a</sup> |             |
| TT        | 6/21     | 0.262       | 0.58 (0.22-1.51) |
| CT+TT vs. CC | 0.557   | 0.86 (0.53-1.41) |
| TT vs. CT+CC | 0.302   | 0.61 (0.24-1.56) |
| T vs. C   | 0.352    | 0.83 (0.56-1.23) |
| CC        | 130/50   | 1 (Ref.)    |             |
| CT        | 113/50   | 0.094       | 1.45 (0.94-2.25) |
| TT        | 20/12    | 0.736       | 1.15 (0.52-2.53) |

### Nondrinker

| H19 rs3024270 | Gender | GG | 91/83 | 1 (Ref.) |
|---------------|--------|----|-------|---------|
|               | Male   | GC | 139/125 | 0.943 | 1.01 (0.69-1.49) |
|               |        | CC | 37/63  | 0.018 | 0.54 (0.33-0.90) |
|               |        | CG+GC vs. GG | 0.394 | 0.85 (0.60-1.23) |
|               |        | CC vs. GC+GG | 0.006 | 0.53 (0.34-0.83) |
|               |        | C vs. G | 0.035 | 0.77 (0.61-0.98) |
|               | Female | GG | 29/37  | 1 (Ref.) |
|               |        | GC | 40/37  | 0.311 | 1.41 (0.73-2.74) |
|               |        | CC | 16/14  | 0.385 | 1.47 (0.62-3.30) |
|               |        | CG+GC vs. GG | 0.266 | 1.42 (0.77-2.64) |
|               |        | CC vs. GC+GG | 0.610 | 1.23 (0.56-2.70) |
|               |        | C vs. G | 0.289 | 1.26 (0.82-1.95) |
| Age          |        | GG | 74/69  | 1 (Ref.) |
|              | <60    | GC | 102/91 | 0.914 | 1.02 (0.66-1.58) |
|              |        | CC | 33/51  | 0.081 | 0.61 (0.35-1.06) |
|              |        | CG+GC vs. GG | 0.526 | 0.88 (0.59-1.32) |
|              |        | CC vs. GC+GG | 0.033 | 0.59 (0.36-0.96) |
|              |        | C vs. G | 0.868 | 0.97 (0.70-1.35) |
|              | >60    | GG | 46/51  | 1 (Ref.) |
|              |        | GC | 77/71  | 0.424 | 1.24 (0.73-2.11) |
|              |        | CC | 20/26  | 0.883 | 0.95 (0.46-1.95) |
| Smoking      |        | GG | 81/56  | 1 (Ref.) |
|              |        | GC | 126/86 | 0.935 | 1.02 (0.65-1.59) |
|              |        | CC | 34/45  | 0.029 | 0.53 (0.30-0.94) |

### Ever smoker

|               | CG+GC vs. GG | 0.445 | 0.85 (0.56-1.29) |
|               | CC vs. GC+GG | 0.009 | 0.51 (0.31-0.85) |
|               | C vs. G | 0.050 | 0.76 (0.58-1.00) |
|               | GG | 39/64  | 1 (Ref.) |
|               | GC | 53/76  | 0.715 | 1.11 (0.65-1.89) |
|               | CC | 19/32  | 0.999 | 1.00 (0.50-2.01) |

### Never smoker

|               | CG+GC vs. GG | 0.731 | 1.09 (0.66-1.81) |

---

<sup>a</sup> OR: Odds Ratio; CI: Confidence Interval.
in the presence of the GC+GG genotype at H19 rs3024270. For H19 rs2839698, the CT+TT genotype was found to be associated with a lower risk of CAD \((P = 0.048, \text{OR} = 8.61, 95\% \text{CI} = 1.02 - 73.03)\) in the presence of the GC+GG genotype at H19 rs3024270. Conversely, for H19 rs3024270, the CC genotype was found to be associated with a lower risk of CAD \((P = 0.034, \text{OR} = 0.61, 95\% \text{CI} = 0.39 - 0.96)\) in the presence of the CT+TT genotype at H19 rs2839698.

### Table 2: Continued.

| Variables          | Genotype         | ACS vs. CON | \(P^a\) | OR (95% CI)  |
|--------------------|------------------|-------------|--------|-------------|
| CC vs. GC+GG       |                  | 0.805       | 0.92   | (0.49-1.74) |
| C vs. G            |                  | 0.920       | 1.02   | (0.72-1.44) |
| Alcohol drinking   |                  |             |        |             |
| Drinker            |                  |             |        |             |
| GG                 |                  | 0.960       | 0.99   | (0.57-1.72) |
| GC                 |                  | 0.135       | 0.56   | (0.26-1.20) |
| CC                 |                  | 0.537       | 0.85   | (0.50-1.44) |
| CC+GC vs. GG       |                  | 0.092       | 0.56   | (0.29-1.10) |
| CC vs. GC+GG       |                  | 0.171       | 0.78   | (0.55-1.11) |
| C vs. G            |                  | 1.29       | 1.29   | (0.81-2.04) |
| GG                 |                  | 0.281       | 0.83   | (0.46-1.50) |
| GC                 |                  | 0.541       | 0.83   | (0.46-1.50) |
| CC                 |                  | 0.539       | 1.14   | (0.75-1.75) |
| Nondrinker         |                  |             |        |             |
| CC+GC vs. GG       |                  | 0.214       | 0.72   | (0.42-1.21) |
| CC vs. GC+GG       |                  | 0.800       | 0.96   | (0.72-1.29) |

\(^a\)Logistic regression adjusted by sex and age. ACS: acute coronary syndrome; CI: confidence interval; CON: control; OR: odds ratio.

### Table 3: Association between haplotype of H19 gene and CAD risk.

| Haplotype | Case (%) | Control (%) | \(P\) | OR (95% CI)  |
|-----------|----------|-------------|------|-------------|
| A C C     | 59.30 (9.65) | 96.99 (14.96) | 0.004 | 0.61 (0.43-0.86) |
| A C G     | 29.96 (48.77) | 35.76 (5.51) | 0.610 | 0.88 (0.53-1.45) |
| G C G     | 347.90 (56.63) | 335.17 (51.68) | 0.078 | 1.22 (0.98-1.52) |
| G T C     | 177.17 (28.84) | 180.56 (27.84) | 0.694 | 1.05 (0.82-1.34) |

SHEsis software (http://analysis.bio-x.cn/) was used for analysis. CAD, coronary artery disease; CI, confidence interval; OR, odds ratio.

### Table 4: Epistatic effect of pair-wise interacting factors on the risks of CAD.

| Interacted pairwise SNPs | Comparison | Subset | CAD vs. CON | \(P\) | OR (95% CI)  |
|--------------------------|------------|--------|-------------|------|-------------|
| H19 rs2735971 interacted with H19 rs2839698 | H19 rs2735971 AA+GA vs. GG | H19 rs2839698 CT+TT | 0.131 | 0.65 (0.37-1.14) |
|                          | H19 rs2735971 AA+GA | H19 rs2839698 CC | 0.017 | 0.59 (0.38-0.91) |
|                          | H19 rs2735971 AA+GA vs. GG | H19 rs2735971 CC | 0.746 | 1.10 (0.61-2.01) |
|                          | H19 rs2735971 AA+GA | H19 rs2735971 GG | 0.673 | 1.08 (0.75-1.58) |
| H19 rs2735971 interacted with H19 rs3024270 | H19 rs2735971 AA+GA vs. GG | H19 rs3024270 GC+GG | 0.021 | 0.64 (0.44-0.93) |
|                          | H19 rs2735971 AA+GA | H19 rs3024270 GG | 0.294 | 0.71 (0.37-1.35) |
| H19 rs2735971 interacted with H19 rs3024270 | H19 rs2735971 AA+GA vs. GG | H19 rs3024270 CC | 0.008 | 0.61 (0.36-1.04) |
|                          | H19 rs2735971 AA+GA | H19 rs3024270 GG | 0.017 | 1.37 (0.97-1.93) |
| H19 rs2839698 interacted with H19 rs3024270 | H19 rs2839698 CT+TT vs. CC | H19 rs3024270 GC+GG | 0.034 | 0.61 (0.39-0.96) |
|                          | H19 rs2839698 CT+TT | H19 rs3024270 GC+GG | 0.071 | 1.37 (0.97-1.93) |
|                          | H19 rs2839698 CT+TT | H19 rs3024270 CC | 0.051 | 0.13 (0.02-1.01) |

All tests were adjusted by age and sex. Statistically significant associations are highlighted in bold \(P < 0.05\). CAD: coronary artery disease; CI: confidence interval; CON: control; OR: odds ratio; SNP: single nucleotide polymorphism.
3.6. Multidimensional Analysis of SNP–SNP Interactions between H19 and CAD. First, we used multiple logistic regression analysis to investigate interactions between H19 SNPs and CAD risk and found that rs2839698 interacted with smoking (Table 5). Next, in order to explore the locus–locus interaction of H19 and CAD, we used multifactor dimensionality reduction (MDR) software to verify the best model for the positive interaction, as shown in Table 6. MDR analyses suggested that the best interaction model was the three-factor model including H19 rs2839698 polymorphism-smoking-drinking; the maximum test accuracy was 0.6979, and the maximum cross-validation consistency was 10/10. Furthermore, we considered H19 rs2839698 polymorphism-smoking-drinking as a risk genotype. According to the number of risks, patients were divided into four groups as follows: 0, 1, 2, and 3 risk genotypes as group 1, group 2, group 3, and group 4, respectively. Adjusting by sex and age, the ORs were 2.32 (1.46–3.70), 1.70 (1.03–2.81), and 0.89 (0.50–1.58). Due to $P_{\text{trend}} = 0.235$, we could only observe a tendency for H19 rs2839698 polymorphism-smoking-drinking interaction with the risk of CAD (Table 7).

3.7. Association between H19 Polymorphisms and Clinical Parameters. As shown in Supplemental Table S2, a dominant model was selected for H19 rs2735971 and rs2839698 polymorphism while a recessive model was chosen for rs3024270 polymorphism. The results indicated that triacylglycerides were lower in the rs2735971 mutant-type (GA+AA) group than in the wild-type group (1.62 ± 1.11 vs. 2.21 ± 2.21; $P = 0.002$). Moreover, wild-type low-density lipoprotein levels were lower for rs3024270 (2.95 ± 0.98 vs. 2.64 ± 1.05; $P = 0.040$). However, no significant association was found with high blood pressure, diabetes, cerebrovascular disease, hyperlipidemia, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, creatinine, urea nitrogen, or trioxypurines among these three polymorphisms. In addition, we analyzed the association of H19 SNPs with the severity of CAD. We did not find any significant associations between the number of coronary artery lesion branches and the three polymorphisms, while under the recessive genetic model of rs3024270, the Gensini score was significantly decreased in the mutant CC genotype than in the GG+GC genotype (45.62 ± 24.49 vs. 54.27 ± 36.29; $P = 0.048$).

4. Discussion

The H19 gene, which contains 5 exons and 3 introns, is located at 11p15.5. This chromosome has multiple binding sites for the transcription factor CCAAT/enhancer-binding protein family [18, 19]. As an lncRNA, H19 lacks an open reading frame and is not a coding protein; its end product is an RNA sequence [20]. However, it can still play a role as a regulatory RNA and participate in coding microRNAs.
Evidence shows that H19 is closely related to cardiovascular diseases. Kim et al. [10, 11, 13, 18–21] suggested that the H19 gene is involved in vascular development, differentiation, and phenotype transformation of vascular smooth muscle. Further, Han et al. found that the H19 gene is highly expressed in human atherosclerotic plaques [13], which may suggest that the risk factors leading to atherosclerosis, such as hyperhomocysteinemia, can significantly increase the expression of H19 in blood vessels [22]. A recent study found that the target miR-103/107 of H19 by Fas-associated with death domain protein participates in the regulation of myocardiial infarction [23]. All of these findings suggest that H19 might be closely related with CAD.

In recent years, an increasing number of studies have investigated H19 gene polymorphisms, which mainly include rs217727, rs2967051, rs2735971, rs2839698, and rs3024270 [24]. Therefore, we hypothesized that H19 polymorphism may be associated with the risk of CAD. To validate our hypothesis, in this study, we assessed the relationship between three SNP loci (rs2735971, rs2839698, and rs3024270) and risk of CAD.

Rs2735971 is a mutation of A/G in the upstream multidrug-resistant region of H19 and prominent in Chinese Han and the Chaoxian (Korean) populations, which makes it a reliable genetic marker [25, 26]. Our study showed that rs2735971 polymorphism significantly reduced the risk of CAD in different genetic models, suggesting that it could be a protective factor against CAD. rs2839698 is a C/T variation within the exon region. Some studies have confirmed that the SNP locus may take part in changing the secondary structure of H19 and could not only abolish the targeting effect between H19 and hsa-miR-24-1-5p, hsa-miR-4486, hsa-miR-566, and hsa-miR-24-2-5p but also increase the number of binding sites of H19 and hsa-miR-612, hsa-miR-5189, hsa-miR1285-3p, and hsa-miR-3187-5p [27]. Moreover, rs2839698 is closely associated with the risk of many kinds of malignant tumors. For instance, Li et al. found that rs2839698 significantly increased the risk of colon cancer in a Chinese Han population and is remarkably associated with the grade of malignancy in colon cancer [27]. Yang et al. suggested that rs2839698 polymorphisms can increase the risk of gastric cancer and that the H19 expression levels in the peripheral blood of CT and TT carriers are significantly higher than those of CC genotype individuals [17]. However, it has been found that the CT genotype of rs2839698 polymorphism could reduce the risk of bladder cancer according to the research of Verhaegh et al. [28]. Our study did not find an association between rs2839698 and CAD in the overall population analysis. However, in a subgroup analysis, we found that the rs2839698 polymorphism decreased the risk of CAD in the women, elderly, and never smoker subgroups, which suggests that the SNPs can be biomarkers in certain subgroups. We suppose that this result may relate to the expression of H19, which is activated by rs2839698. rs3024270 is a mutation of C/G in the intron region. Li et al. analyzed the incidence of colorectal cancer in Chinese Han patients but found no correlation between rs3024270 and the risk of colon cancer [17]. Our study found that the recessive model reduced the risk of CAD in overall population analysis. In further stratified analysis, we found that the risk of CAD was reduced by rs3024270 polymorphism in the men, younger age, and smoker subgroups, suggesting that rs3024270 polymorphism might be a protective factor for CAD risk in certain subgroups.

The pathogenesis of CAD has not yet been fully elucidated. The common view in the current academic community is that CAD is probably a polygenic heredity disease affected by multiple genetic and environmental factors [29]. We used logistic regression analysis and MDR software analysis to study the relationship between the SNP–SNP and SNP–environment interactions of H19 and the risk of CAD, respectively. MDR software [30] was used to calculate the best prediction model, and the prediction error of the training samples was measured by the test sample (the rest of the sample), while evaluation of the extent of the cross-validation consistency was used. Thus, we chose the combination model with the maximum test accuracy and the maximum cross-validation consistency among the results. The
interactions between multiple SNP loci in H19 with environmental factors were further analyzed. Our study found that H19 rs2839698 polymorphism interacted with smoking, and further analysis found that this SNP combined with smoking and drinking made the best model for predicting the risk of CAD. Moreover, the three polymorphisms interacted with each other in epistatic effect analysis. These results all indicate that a combination of biomarkers provides a better prediction of the risk of CAD.

In our study, we found that the contribution of the dominant model of H19 rs2735971 polymorphism to the disease was protective. In addition, carriers with this SNP genotype were less likely to have hypertriglyceridemia, which is consistent with our previous risk studies. The contribution of the recessive model of H19 rs3024270 polymorphism to the disease also demonstrated a protective tendency (although it did not reach statistical significance). In a previous study of a relationship between the polymorphism and the clinical features, we found that the patients with the variant type were less likely to develop hypo-high-density lipoprotein cholesterol. We did not obtain a positive result in the analysis of clinical features and H19 rs2839698 polymorphism, which suggests that this polymorphism might not influence the clinical features of CAD.

In addition, we used the number of coronary arteries and Gensini score to assess coronary disease severity in our study. We found that the recessive genetic model of rs3024270 could predict the severity of CAD. However, no significant relationship was observed between rs2735971, rs2839698, and severity of CAD.

4.1. Limitations. There were several limitations to our study. First, the sample size was not sufficiently large. The populations selected in our research were all Han people in Liaoning Province. Therefore, the results of our study need to be validated in larger samples, in other regions, and among other ethnic groups. Second, the SNP loci in our study were all located in the intron region, so the underlying mechanisms of the effect of SNP site on the function of H19 require further examination. Third, the largest CAD GWAS available (CARDioGRAMPlusC4D) showed that it was the most significant. In addition, we failed to add these lncRNAs in this study. However, our study was an exploratory study and the results verified by GWAS indicate the direction to take in the future. Finally, we calculated the test effectiveness. Although some of the loci were not significant, there were some indications for exploring the SNPs of CAD and clues for future clinical applications.

5. Conclusion

In summary, our study demonstrated that some genotypes of polymorphisms rs2735971, rs2839698, and rs3024270 of H19 were associated with the risk and severity of CAD in a Chinese population and might help to predict the risk of CAD in the future. We also found that rs2735971-rs2839698-rs3024270 A-C-C may have a significantly lower risk of CAD. The recessive genetic model of rs3024270 could predict the severity of CAD.

Data Availability

Answer: No. Comment: We agree to share the data underlying the findings of our manuscripts.

Conflicts of Interest

The authors declare that there is no conflict of interest that could be perceived as prejudicial to the impartiality of the reported research.

Authors’ Contributions

Yuan-ze Jin designed the study and corrected the manuscript. Wei-na Hu conducted laboratory work, data analysis and drafted the manuscript. Han-xi Ding and Qian Xu conducted data analysis. Xue-ying Zhang and Da-tong Yang recruited participants and collected blood samples.

Acknowledgments

This work was supported partly by grants from the Science and Technology Program in Liaoning Province (Nos. 2017011037-301 and 2018010687-301).

Supplementary Materials

Characteristics of the subjects. (Supplementary Materials)

References

[1] A. E. Moran, M. H. Forouzanfar, G. A. Roth et al., “Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study,” Circulation, vol. 129, no. 14, pp. 1483–1492, 2014.
[2] Z. Manlu, W. Wen, W. Yongjui, W. Zhao, and L. Huij, “Reports of cardiovascular diseases in China at 2017,” China circulation journal, vol. 33, pp. 1–8, 2018.
[3] R. McPherson, A. Pertsemilids, N. Kavasl et al., “A common allele on chromosome 9 associated with coronary heart disease,” Science, vol. 316, no. 5830, pp. 1488–1491, 2007.
[4] A. Rosenzweig, “Scanning the genome for coronary risk,” The New England Journal of Medicine, vol. 357, no. 5, pp. 497–499, 2007.
[5] S. Kathiresan, O. Melander, C. Guiducci et al., “Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans,” Nature Geneteces, vol. 43, no. 2, pp. 189–197, 2008.
[6] M. B. Clark and J. S. Mattick, “Long noncoding RNAs in cell biology,” Seminars in Cell & Developmental Biology, vol. 22, no. 4, pp. 366–376, 2011.
[7] M. Maziad, P. Benson, A. Gluba-Brzozka, J. Rysz, and M. Banach, “Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease,” Journal of Clinical Lipidology, vol. 11, no. 3, pp. 617–623, 2017.
[8] T. Wu and Y. Du, “LncRNAs: from basic research to medical application,” International Journal of Biological Sciences, vol. 13, no. 3, pp. 295–307, 2017.
[9] D. Yu, C. Tang, P. Liu, W. Qian, and L. Sheng, “Targeting lncRNAs for cardiovascular therapeutics in coronary artery disease,” Current Pharmaceutical Design, vol. 24, 2018.
10. C. X. Li, H. G. Li, L. T. Huang et al., “H19 IncRNA regulates keratinocyte differentiation by targeting miR-130b-3p,” Cell Death & Disease, vol. 8, no. 11, article e3174, 2017.

11. C. Shi, L. Zhang, and C. Qin, “Long non-coding RNAs in brain development, synaptic biology, and Alzheimer’s disease,” Brain Research Bulletin, vol. 132, pp. 160–169, 2017.

12. Y. Zhang and B. Tycko, “Monoallelic expression of the human H19 gene,” Nature Genetics, vol. 1, no. 1, pp. 40–44, 1992.

13. D. K. Han, Z. Z. Khaing, R. A. Pollock, C. C. Haudenschild, and G. Liu, “H19, a marker of developmental transition, is reexpressed in human atherosclerotic plaques and is regulated by the insulin family of growth factors in cultured rabbit smooth muscle cells,” The Journal of Clinical Investigation, vol. 97, no. 5, pp. 1276–1285, 1996.

14. D. A. Weiner, T. J. Ryan, C. H. McCabe et al., “Value of exercise testing in determining the risk classification and the response to coronary artery bypass grafting in three-vascular coronary artery disease: a report from the Coronary Artery Surgery Study (CASS) registry,” The American Journal of Cardiology, vol. 60, no. 4, pp. 262–266, 1987.

15. G. G. Gensini, “A more meaningful scoring system for determining the severity of coronary heart disease,” The American Journal of Cardiology, vol. 51, no. 3, p. 606, 1983.

16. S. AbdulAzeez, A. al-Nafee, A. al-Shehri et al., “Intronic polymorphisms in the CDKN2B-AS1 gene are strongly associated with the risk of myocardial infarction and coronary artery disease in the Saudi population,” International Journal of Molecular Sciences, vol. 17, no. 3, p. 395, 2016.

17. C. Yang, R. Tang, X. Ma et al., “Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han population,” Oncotarget, vol. 6, no. 17, pp. 15311–15320, 2015.

18. D. K. Kim, L. Zhang, V. J. Dzau, and R. E. Pratt, “H19, a developmentally regulated gene, is reexpressed in rat vascular smooth muscle cells after injury,” The Journal of Clinical Investigation, vol. 93, no. 1, pp. 355–360, 1994.

19. A. Gabory, M. A. Ripoche, T. Yoshimizu, and L. Dandolo, “The H19 gene: regulation and function of a non-coding RNA,” Cytogenetic and Genome Research, vol. 113, no. 1-4, pp. 188–193, 2006.

20. C. I. Brannan, E. C. Dees, R. S. Ingram, and S. M. Tilghman, “The product of the H19 gene may function as an RNA,” Molecular and Cellular Biology, vol. 10, no. 1, pp. 28–36, 1990.

21. M. Zhu, Q. Chen, X. Liu et al., “IncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI,” The FEBS Journal, vol. 281, no. 16, pp. 3766–3775, 2014.

22. A. M. Devlin, T. Bottiglieri, F. E. Domann, and S. R. Lentz, “Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia,” The Journal of Biological Chemistry, vol. 280, no. 27, pp. 25506–25511, 2005.

23. J. X. Wang, X. J. Zhang, Q. Li et al., “MicroRNA-103/107 regulate programmed necrosis and myocardial ischemia/reperfusion injury through targeting FADD,” Circulation Research, vol. 117, no. 4, pp. 352–363, 2015.

24. Z. Lv, Q. Xu, and Y. Yuan, “A systematic review and meta-analysis of the association between long non-coding RNA polymorphisms and cancer risk,” Mutation Research, vol. 771, pp. 1–14, 2017.

25. X. Y. Ma, W. Z. He, Y. Tian et al., “The SNPs in upstream methylation region of H19 gene in the Han population of Guangdong Province,” Journal of Forensic Medicine, vol. 32, pp. 184–188, 2016.

26. W. T. Wei, X. Wang, D. M. Wang et al., “The distributions of SNPs in upstream methylation region of H19 gene in the Chaoxian population,” Journal of Forensic Medicine, vol. 29, pp. 360–364, 2013.

27. S. Li, Y. Hua, J. J. Jin et al., “Association of genetic variants in IncRNA H19 with risk of colorectal cancer in a Chinese population,” Oncotarget, vol. 7, no. 18, pp. 25470–25477, 2016.

28. G. W. Verhaegh, L. Verkleij, S. H. Vermeulen, M. den Heijer, J. A. Witjes, and L. A. Kiemenev, “Polymorphisms in the H19 gene and the risk of bladder cancer,” European Urology, vol. 54, no. 5, pp. 1118–1126, 2008.

29. M. V. Sasidhar, S. Reddy, A. Naik, and S. Naik, “Genetics of coronary artery disease - a clinician’s perspective,” Indian Heart Journal, vol. 66, no. 6, pp. 663–671, 2014.

30. L. W. Hahn, M. D. Ritchie, and J. H. Moore, “Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions,” Bioinformatics, vol. 19, no. 3, pp. 376–382, 2003.